Actionable news
All posts from Actionable news
Actionable news in SRPT: Sarepta Therapeutics, Inc.,

JMP Securities Chimes In on Sarepta Therapeutics Inc (SRPT) Following 2Q Update; Awaits FDA Decision on Eteplirsen

JMP Securities analyst Liisa Bayko was out with a research note on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), after the biotech company released uneventful second-quarter results and provided a corporate update. The analyst remains bearish on shares, reiterating an Underperform rating, with a price target of $10.00; a 55% decrease from where SRPT stock is currently trading.

Sarepta reported a wider loss than Bayko’s projection of $1.15 earnings per share with a reported loss of $1.35 earnings per share. Bayko believes that having closed 2Q:16 with $123 million...